Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
Launched by UNIVERSITY OF MICHIGAN · Nov 1, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking to improve treatments for people with diarrhea-predominant Irritable Bowel Syndrome (IBS-D). The study will help researchers understand how well a medication called rifaximin works for patients with IBS-D. Participants will be asked to complete online surveys and take part in some tests, including a hydrogen breath test, which can provide helpful information about their digestive health. The trial is currently recruiting individuals aged 18 to 74 who meet specific criteria, such as having IBS-D symptoms and keeping a diary of their symptoms for at least five days.
To be eligible for the study, participants should not be pregnant or breastfeeding, and they should not have certain other health conditions like inflammatory bowel disease or recent gastrointestinal infections. During the study, participants can expect to receive rifaximin as part of their treatment while also undergoing some tests and questionnaires to track their symptoms. This research is important because it aims to find better ways to help those suffering from IBS-D, which can significantly impact daily life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • IBS-D (Rome IV Diagnostic Criteria)
- • Diary compliance for at least 5 days and no rescue medications during baseline
- • Appropriate levels of abdominal pain and diarrhea
- Exclusion Criteria:
- • Pregnant women or planning on becoming pregnant while in the study, or lactating women while in the study
- • Inflammatory bowel disease, diabetes mellitus, systemic sclerosis, or celiac disease
- • Active gastrointestinal or hematological malignancy which requires ongoing treatment
- • Surgery to the GI tract in the past 3 months
- • Gastrointestinal infection or diverticulitis in the past 3 months
- • Severe hepatic impairment
- • Any use of antibiotics in the past month
- • Current use of probiotics
- • Any history of allergies to rifaximin or its derivatives
- • Any comitant use of P-glycoprotein inhibitors (for example. Cyclosporine)
- • Known allergies to glucose or lactulose
About University Of Michigan
The University of Michigan, a leading academic institution renowned for its commitment to advancing healthcare and medical research, serves as a prominent clinical trial sponsor. With a robust infrastructure that supports innovative research initiatives, the university leverages its multidisciplinary expertise to conduct a wide array of clinical trials aimed at improving patient outcomes and advancing medical knowledge. Through its state-of-the-art facilities and collaborative environment, the University of Michigan fosters partnerships between researchers, clinicians, and industry leaders, ensuring the development of cutting-edge therapies and interventions that address pressing health challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Ann Arbor, Michigan, United States
Patients applied
Trial Officials
William Chey, M.D.
Principal Investigator
University of Michigan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials